News

The Food and Drug Administration (FDA) granted an accelerated approval to atezolizumab (Tecentriq) to be used as a frontline treatment for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma (mUC).

The FDA has eliminated the need for REMS certification before administration of ESAs for anemia due to myelosuppressive chemotherapy.

Amanda Bontempo, MS, RD, CSO, CDN, gives some tips for healthy eating. Join us on 4/18 at 1 PM for our tweetchat, with Bontempo as moderator, to discuss more nutrition.

Thought the incidence of breast cancer has decreased in many US racial/ethnic populations, the rate has increased in the Asian-American population.

After losing her husband to stage III esophageal cancer, Mindy Mordecai came together with top physicians, business leaders and families affected by the disease to found Esophageal Cancer Action Network (ECAN).

There may be a shift away from the USPSTF's opposition to routine PSA screening for prostate cancer in some men.

A recent study determined that an education initiative could help to ease worries patients with cancer may have about palliative care, thus improving quality of life.

As prevalence of HPV within the population rises, incidence of HPV-related cancers is expected to rise.

For adolescent and young adult patients with cancer, navigating social life after their diagnosis can be difficult.

A recent review has found substantial evidence linking androgen deprivation therapy (ADT) to dementia in patients with prostate cancer.

Tricia Strusowski, MS, RN, discusses the importance of a nurse navigator to both the patient and the center.

With antiretroviral drugs easing the burden of AIDS-defining cancers in HIV-positive patients, the most common cancers in this population are expected to shift to those associated with aging.

A new policy statement from ASCO addresses the specific needs in oncology of patients in the sexual and gender minority populations.

A recent meta-analysis found that the most effective treatments for cancer-related fatigue are exercise and psychological interventions.

People with certain disabilities were found to be less likely to follow recommended guidelines for colorectal cancer screening.

Sixteen percent of patients with metastatic non-small cell lung cancer (NSCLC) receiving nivolumab survived after 5 years.

A shorter length of sleep may lead to an increased risk of death from prostate cancer, according to a recent study presented at the 2017 AACR Annual Meeting.

According to findings presented at the 2017 AACR Annual Meeting, aspirin use was associated with lower mortality in colorectal cancer.

Fewer people are dying from cancer than years ago, according to a recent study.

For patients with glioblastoma multiforme (GBM), tumor treating fields (TTFields) reduced the risk of death by 37% and extended overall survival by a median of 5 months.

For patients with cancer, smoking cessation should include counseling and pharmacology. Encouragement throughout, especially if a patient relapses is important.

A recent study found that individuals who had the chickenpox virus when they were younger were less likely to eventually develop gliomas.

Subcutaneous co-formulation of rituximab for treatment of patients with certain types of lymphoma and leukemia advances toward approval.

John E. Mullinax, M.D., discusses a chemotherapy strategy, isolated limb infusion, that may be able to save the limbs of some patients with sarcoma.

A recent study has found that pembrolizumab (Keytruda) may be effective in treating patients with mesothelioma.

Expert Adam M. Brufsky, MD, PhD, discusses the considerations for bone-targeted agents denosumab and zoledronic acid (Zometa) in patients with breast cancer.

Kula for Karma, a nonprofit organization, offers yoga programs designed to aid patients with cancer as well as medical professionals, first responders and others, manage stress and improve quality of life.

The FDA has issued an advisory on the association between breast implants and anaplastic large cell lymphoma. More research is needed in this area.

The FDA has granted approval for the PARP inhibitor niraparib for maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial repsponse to platinum-based chemotherapy.

For patients with breast cancer on aromatase inhibitors, preventive sexual counseling can reduce sexual dysfunction, and it should be provided earlier in treatment, with support from providers.